Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results

[Business Wire] – Esperion Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of hypercholesterolemia, t more

View todays social media effects on ESPR

View the latest stocks trending across Twitter. Click to view dashboard

See who Esperion is hiring next, click here to view